A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
ID Number 08-0723Principal Investigator(s)
Zahi A Fayad
Department(s) or Division(s)
Mount Sinai Translational and Molecular Imaging Institute
The purpose of this study is to look at the safety and effectiveness of an investigational drug called BMS-582949 compared to placebo (looks like the study drug but does not have any medicine in it) and atorvastatin (Lipitor™), a lipid-lowering therapy. BMS-582949 is currently being developed for the treatment of rheumatoid arthritis and psoriasis and has the potential to reduce inflammation in the arteries. Atherosclerosis is a disease that builds fat deposits inside the arteries, leading to vascular inflammation and other health problems like stroke, heart attack or arterial occlusion in the legs.
Zahi A. Fayad, PhD
Recruiting Patients: Yes